Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for auto ...

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company approved the issuance of an option to purchase 2,600 shares of the Company’s common sto ...

Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale r ...

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class ...

On Thursday, Palisade Bio Inc PALI stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.Palisade Bio priced an underwritten public offering for gross proceeds of approximately $5 million.The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249.The Common Warrants will have an exercise price of $1.40 per share, will be exe ...

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for PALI-2108 for ...

Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inh ...

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the third quarter of 2024 and provi ...

融资情况 - 2024年5月完成私募融资净现金收益约350万美元（总现金收益400万美元减去约50万美元的现金股权发行成本）[111] - 2024年2月完成权证诱导交易净现金收益约220万美元（总现金收益250万美元减去约30万美元的现金股权发行成本）[111] - 2024年5月6日完成普通股私募等融资活动获得毛现金收益400万美元净现金收益约350万美元[133] - 2024年2月1日权证诱导活动净现金收益约220万美元[135] - 2024年前9个月融资活动提供的现金约为540万美元[141] - 2023年前9个月融资活动提供的现金约为1130万美元[142] 现金及运营支撑 - 截至2024年9月30日现金及现金等价物余额为800万美元足以支撑计划到2025年第一季度的运营[111] - 截至2024年9月30日公司拥有现金、现金等价物和受限现金810万美元[138] - 2024年前三季度经营活动使用净现金981.2万美元投资活动使用净现金0融资活动提供净现金542万美元[138] - 2024年前9个月经营活动使用的净现金约为980万美元[139] - 2023年前9个月经营活动使用的净现金约为840万美元[139] - 截至2024年9月30日公司现金及现金等价物余额为800万美元[146] - 公司认为现有现金可支撑计划中的运营至2025年第一季度[146] 收入情况 - 2023年9月30日止九个月从与Newsoara的合作协议中确认约30万美元的许可收入，2024年无许可收入[112] 研发相关 - 研发费用在2024年前九个月主要与PALI - 2108的临床前活动有关且2024年第三季度相关成本增加后续还会增加[114] - 2024年10月9日加拿大卫生部批准PALI - 2108的1期临床研究已开始招募并于11月6日对首批受试者用药[110] - 计划2025年向美国FDA提交IND申请若获批2025年下半年在美国开展临床试验[107] - 1期临床研究计划招募约90名受试者预计2025年第二季度公布初步数据[110] - 若1期试验达到主要目标计划2025年下半年启动1b/2a期临床研究[110] - 2024年第三季度研发费用为213.7万美元较2023年同期增长2%[121] - 2024年前三季度研发费用为697.9万美元较2023年同期增长26%[125] 费用与亏损 - 2024年第三季度一般和管理费用为145.6万美元较2023年同期下降13%[121] - 2024年前三季度一般和管理费用为449.8万美元较2023年同期下降3%[125] - 2024年第三季度净亏损348.7万美元较2023年同期下降3%[121] - 2024年前三季度净亏损1109.4万美元较2023年同期增长19%[125] 其他财务相关 - 公司总部办公空间租赁剩余未来最低租赁付款约为12.8万美元[144] - 截至2024年9月30日保险融资安排剩余余额约为20万美元[145] 会计政策相关 - 2024年3月31日止的三个月确定衍生金融工具会计政策不再是关键会计政策[147] - 公司被视为小型报告公司无需提供市场风险的定量和定性披露[150] 持续经营能力评估 - 公司管理层评估了对持续经营能力产生重大怀疑的条件和事件[118]

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceuti ...